Tackling Global Challenges in an Aging Era… "Aspiring to become a global research and treatment hub for the rare neurodegenerative disease" SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ -- Seoul ...
- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment PSP is a degenerative disease that, like Parkinson's disease, causes symptoms such ...
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global progressive supranuclear palsy treatment market is estimated to be valued at US$ 14.38 million in 2020 and is expected to ...
On October 13, GemVax & KAEL announced that it held a plaque unveiling ceremony for the "International Progressive Supranuclear Palsy Research and Treatment Center" at Bundang Seoul National ...
Progressive supranuclear palsy (PSP) is a rare, degenerative neurological condition. It usually starts in middle age and can cause symptoms similar to those of Parkinson’s disease. PSP can cause ...
MOU Signed Among SNUBH-CurePSP-GemVax for the Establishment of International PSP Research and Treatment Center Tackling Global Challenges in an Aging Era… "Aspiring to become a global research and ...
SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- GemVax & KAEL Co., Ltd. ("GemVax"; KOSDAQ ticker: 082270) announced that topline results of a Phase 2a clinical trial (the "Phase 2a PSP Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback